Repligen Corporation is a specialized life sciences company focused on the development, production, and commercialization of bioprocessing technologies used in the manufacture of biologic drugs, such as monoclonal antibodies, recombinant proteins, and gene therapies. The company's business model centers on providing high-value consumables, equipment, and analytics that enable biopharmaceutical manufacturers and contract development and manufacturing organizations (CDMOs) to improve process efficiencies, flexibility, and product yields. Repligen's product portfolio is organized into four main franchises: Filtration, Chromatography, Proteins, and Process Analytics. Key offerings include OPUS single-use chromatography columns, ATF (Alternating Tangential Flow) systems for cell culture intensification, and specialized Protein A ligands used in downstream purification. The company generates the vast majority of its revenue from the sale of these bioprocessing consumables and related equipment. Geographically, Repligen operates on a global scale, with significant revenue contributions from North America, Europe, and the Asia-Pacific region. Competitively, Repligen has established itself as a pure-play bioprocessing leader through a combination of internal innovation and strategic acquisitions. By focusing exclusively on the bioprocessing workflow since 2012, the company has built a highly differentiated portfolio that addresses critical bottlenecks in biologic drug production. Its strong market position is supported by the increasing industry shift toward single-use technologies and continuous manufacturing processes.
